New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:16 EDTENDP, NQ, SPPI, ARNA, GTAT, CASI, BDSI, DISHOn The Fly: Pre-market Movers
HIGHER: DISH (DISH), up 2.4% following positive mention in this weekend's Barron's, contending the shares could climb 20%... BioDelivery Sciences (BDSI), up 15% after announcing results from its Endo buprenorphine trial with an Endo (ENDP) division... CASI Pharmaceuticals (CASI), up 3.7% after confirming that it received FDA orphan drug designation for a drug... Spectrum (SPPI), up 3% after being granted accelerated approval for Beleodaq from FDA. LOWER: GT Advanced (GTAT), down 10% after downgraded at UBS and Cannaccord... NQ Mobile (NQ), down 3.5% after Muddy Waters says the company has likely already decided to fire PwC... Arena Pharmaceuticals (ARNA), down 3% after Chairman, President and CEO Jack Lief sold 223,525 shares of the company's common stock pursuant to a Rule 10b5-1 trading plan on July 1, according to a regulatory filing from late Thursday.
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
07:07 EDTDISHJefferies calls Viacom an attractive value play in media
Subscribe for More Information
November 20, 2015
07:02 EDTSPPISpectrum submits IND to FDA to initiate Phase 2 breast cancer study
Spectrum Pharmaceuticals announced today the company has submitted an IND application to the U.S. Food and Drug Administration and plans to initiate a Phase 2 breast cancer study in the U.S. as soon as possible. The Phase 2 study is planned to be an open-label study that will enroll approximately 70 patients with HER-2 positive metastatic breast cancer, who have failed at least one or more HER-2 directed therapy. The dose and schedule of oral poziotinib will be based on clinical experience from the studies in Korea, and in addition include the use of prophylactic therapies to help minimize known side-effects of HER2-directed therapies.
November 18, 2015
13:07 EDTENDPFTC approves final order settling charges over Endo, Par merger
Subscribe for More Information
06:58 EDTNQNQ Mobile enters into binding agreement to sell Beijing Tianya
NQ Mobile announced it has entered into a legally binding agreement to sell 100% of the equity interest in Beijing Tianya , which operates NQ Mobile's mobile health applications related business, to Tack Fiori International Group, a Cayman Islands company listed in Hong Kong, for an aggregate consideration of $40M. Beijing Tianya is a wholly owned subsidiary of Beijing NQ Technology Co., Ltd., NQ Mobile's consolidated affiliated entity in China. The company's board has approved both the transaction and the Agreement. The closing of the transaction is subject to the condition that Tack Fiori obtains the necessary approvals, including shareholder approval, to complete the transaction, as well as additional customary closing conditions, and the satisfaction and compliance of all relevant requirements under the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange Limited.
05:35 EDTSPPISpectrum divests rights to Zevalin in Japan, other countries
Spectrum Pharmaceuticals announced the divestment of Zevalin rights in Japan and other countries in Asia Pacific, Middle East, Africa and Latin America, to Mundipharma. Spectrum will receive an up-front payment of $15M plus $5M in profits on initial Zevalin supply. Spectrum will continue to own Zevalin rights for U.S., Canada, and Europe.
November 17, 2015
16:59 EDTENDPDepomed acquires U.S. rights to pain product from Grunenthal
Subscribe for More Information
15:19 EDTBDSIBioDelivery Sciences management to meet with William Blair
Meeting to be held in London on November 17 hosted by William Blair.
08:04 EDTENDPStifel to hold a conference
Subscribe for More Information
November 16, 2015
09:06 EDTENDPDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
07:16 EDTENDPHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).
06:06 EDTENDPEndo downgraded to Neutral from Buy at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use